The tumor suppressor protein BARD1 plays a dual role in response to genotoxic stress: DNA repair as a BARD1-BRCA1 heterodimer and induction of apoptosis in a BRCA1-independent manner. We have constructed a series of BARD1 deletion mutants and analysed their cellular distribution and capacity to induce apoptosis. As opposed to previous studies suggesting an exclusively nuclear localization of BARD1, we found, both in tissues and cell cultures, nuclear and cytoplasmic localization of BARD1. Enhanced cytoplasmic localization of BARD1, as well as appearance of a 67 kDa C-terminal proteolytic cleavage product, coincided with apoptosis. BARD1 translocates to the nucleus independently of BRCA1. For recruitment to nuclear dots, however, the BRCA1-interacting RING finger domain is required but not sufficient. Protein levels of N-terminal RING finger deletion mutants were much higher than those of fulllength BARD1, despite comparable mRNA levels, suggesting that the N-terminal region comprising the RING finger is important for BARD1 degradation. Sequences required for apoptosis induction were mapped between the ankyrin repeats and the BRCT domains coinciding with two known cancer-associated missense mutations. We suggest that nuclear and cytoplasmic localization of BARD1 reflect its dual function and that the increased cytoplasmic localization of BARD1 is associated with apoptosis.
Introduction
A function of BARD1 in a pathway of stress-induced signaling towards apoptosis was discovered previously (Irminger-Finger et al., 2001) . Overexpression of BARD1 inducing apoptosis in a number of cell lines, and genotoxic stress triggering apoptosis is accompanied by upregulation of BARD1. Thus, BARD1 serves as a mediator between proapoptotic stress signals and p53-dependent apoptosis. In line with its tumor suppressor function, depletion of BARD1 protein in vitro through antisense BARD1 mRNA or ribozyme expression, annihilates p53 upregulation and apoptotic response to stress and leads to genomic instability and a premalignant phenotype (Irminger-Finger et al., 1998 , 2001 Soriano et al., 2000) . BARD1 is implicated in a number of other functions most of them dependent on its interaction with the tumor suppressor protein BRCA1, of which it is the major binding partner in a yeast twohybrid screen (Wu et al., 1996) . BRCA1 and BARD1 heterodimerize through their respective N-terminal RING finger domains (Meza et al., 1999) . Association of the C64G mutation within the Nterminal RING finger of BRCA1 with familial breast and ovarian cancer (Wu et al., 1996; Ruffner et al., 2001) suggests a relevant function for the BRCA1-BARD1 interaction in tumor suppression. Structural analysis of the BARD1-BRCA1 heterodimeric complex by NMR (Brzovic et al., 2001b) and mutational analysis demonstrated that abolishing heterodimer formation (Morris et al., 2002) results in genomic instability, uncontrolled cell proliferation and tumorigenesis (Baer, 2001; Parvin, 2001) .
Evidence for BARD1/BRCA1 heterodimer formation in vivo comes from the observation that BARD1 colocalizes with BRCA1 and the repair protein Rad51 in nuclear dots during S phase (Jin et al., 1997) and to nuclear foci in response to DNA damage (Scully et al., 1997b) . Mutations in the RING finger of BRCA1, disrupting BRCA1/BARD1 interactions, annihilate the formation of nuclear foci (Chiba and Parvin, 2002; Fabbro et al., 2002) , which suggests that the interaction with BARD1 is required for this localization.
A recent report shows that BARD1 plays a role as chaperone for the correct translocation of BRCA1 into the nucleus (Fabbro et al., 2002) . Deletion of the BRCA1-RING domain leads to exclusion of BRCA1 from the nucleus, and a BRCA1 mutant lacking NLS, but retaining the RING domain structure, is translocated to the nucleus by BARD1 overexpression. Most importantly, the binding of BARD1 inhibits the nuclear export of BRCA1 by masking its nuclear export signal (NES) (Brzovic et al., 2001a; Fabbro et al., 2002) . Since more than 75% of all BRCA1 is complexed with BARD1 (Baer and Ludwig, 2002) , BARD1 plays an important role in trapping BRCA1 within the nucleus. Whether BARD1 itself depends on other proteins for entering and exiting the nucleus has not been determined.
The BRCA1/BARD1 heterodimer exhibits ubiquitin ligase activity, which is abolished by mutations within the RING finger domain of BRCA1 (Hashizume et al., 2001; Chen et al., 2002) . BARD1 supports the association of BRCA1 with Polymerase II holoenzyme, a suspected target of BARD1/BRCA1 ubiquitylation, which is abrogated by a deletion of the BRCA1-RING finger domain (Chiba and Parvin, 2002) . Furthermore, the stability of BARD1 and BRCA1 proteins themselves might be controlled by ubiquitylation (Mallery et al., 2002; Xia et al., 2003) . Besides degradation, ubiquitylation can act as a regulator of nuclear-cytoplasmic shuttling, as described for the nuclear export of p53 (Gu et al., 2001; Lohrum et al., 2001) . A similar mechanism might exist in the case of BARD1 and BRCA1, in particular since BARD1 and BRCA1 become ubiquitinylated upon association (Chen et al., 2002) . It was suggested that nuclear-cytoplasmic shuttling has functional implications since BARD1 and BRCA1 are less prone for degradation when bound together but their dissociation after ubiquitylation could lead to nuclear export and degradation .
In addition to its interaction with BRCA1, BARD1 associates with a number of other proteins involved in different functions (Irminger-Finger and Leung, 2002) , all of which imply a nuclear localization such as mRNA polyadenylation factor CstF50 (Kleiman and Manley, 1999; Kleiman and Manley, 2001) , the NFK-B regulator oncoprotein Bcl-3 (Dechend et al., 1999) , the complex containing BRCA1 and CtIP (Yu and Baer, 2000) , and the Ewing's sarcoma protein EWS (Spahn et al., 2002) .
BARD1 structurally relates to BRCA1, as it contains N-terminal RING finger and C-terminal BRCT domains (Wu et al., 1996; Ayi et al., 1998) ; however, novel functions of BARD1 might relate to its ankyrin repeats, which are found in proteins with very diverse functions, and to regions without known protein motifs. Here, we report that BARD1 is found in the nucleus and the cytoplasm and that its apoptotic function is associated with its cytoplasmic localization. Furthermore, by mapping the regions responsible for intracellular localization or required for its apoptotic function, using an enhanced green fluorescent protein (EGFP), tagged to the C-terminal end of full-length BARD1 or various deletion variants, we demonstrate their respective dynamic intracellular localization and the correlation of cytoplasmic localization and apoptotic activity.
Results

Cytoplasmic localization of BARD1
The tissues with the highest expression of BARD1 and BRCA1 mRNAs are spleen and testis (Wu et al., 1996; Ayi et al., 1998; Irminger-Finger et al., 1998) . In the spleen, a BRCA1-associated function of BARD1 could be expected, as well as a function in apoptosis. We applied immunohistochemistry to detect the BARD1 protein in the spleen. BARD1 staining was observed in the red pulp and the white pulp, both regions known for the high turnover of lymphocytes (Figure 1a) . The intracellular localization of BARD1 was both nuclear and cytoplasmic and in some cells exclusively cytoplasmic (Figure 1a) .
It was interesting to determine the intracellular localization of BARD1 in tissues where BARD1 is upregulated in response to cellular stress. In the brain, no BARD1 expression can be found normally but maximum BARD1 expression is observed in the regions adjacent to the stroke induced by ischemia (IrmingerFinger et al., 2001) , in the penumbra, where apoptosis has been described (Ferrer and Planas, 2003) . Immunohistochemisty on mouse brain sections after ischemia demonstrates that the intracellular localization of BARD1 is rather cytoplasmic than nuclear (Figure 1b) . ) is shown in a mouse brain after ischemia. Penumbra region is shown in overview in ( Â 4.5). BARD1 staining is cytoplasmic in most cases, as exemplified by arrows in higher magnifications in ( Â 40). Bar 100 mm Nuclear-cytoplasmic translocation of BARD1 CE Jefford et al
Strong evidence for cytoplasmic localization of BARD1 protein is the observed staining of protrusions of neuronal cells (Figure 1b) . Control staining without primary antibody or in the presence of antigenic peptide did not produce staining (not shown). Antibodies against the N-terminal and the C-terminal portion of the protein present the same distribution. These data suggest that in vivo, apoptosis, occurring physiologically or induced upon stress, is accompanied by a cytoplasmic localization of BARD1, and that the apoptotic function of BARD1 might be confined to the cytoplasm.
Subcellular distribution of BARD1 in vitro
Previous reports stipulate that BARD1 is found in nuclear extracts and localizes to BRCA1 foci in the nucleus during the S phase (Jin et al., 1997; Scully et al., 1997a) and to distinct intranuclear foci upon genotoxic stress (Scully et al., 1997a) . To explore the dynamics of BARD1 localization at various stages of the cell cycle and apoptosis, immunofluorescent staining and electron microscopy (EM) were performed on NIH 3T3 cells ( Figure 2 ). Immunoreactivity with anti-BARD1 antibodies results in a punctuate staining in the nucleus of interphase cells but diffuse staining in the cytoplasm as well (Figure 2a ). Similar results were obtained when BARD1 protein localization was assayed in other cell lines (TAC2, HEK 293T, HeLa) and when other antibodies (N-19, C-20, H300) were used ( Figure 2b ). Enhanced staining of BARD1 in nuclear dots is obtained by confocal microscopy. By EM, immunoreactive dots of BARD1 were identified in the nucleus and with similar frequency in the cytoplasm (Figure 2c ) corroborating the data obtained by immunofluorescence. Interestingly, we also observed that cells progressing through mitosis accumulate higher levels of BARD1 than G1 or S-phase cells. BARD1 is excluded from the condensed chromatin during metaphaseanaphase stages of mitosis ( Figure 2a ). This localization of BARD1 contrasts with the reported binding of BRCA1 to the centrosomes during mitosis (Hsu and White, 1998; Deng, 2002; Lotti et al., 2002) . Our data suggest that BARD1 might have a specific function in the cytoplasm, and that BARD1 is not engaged in functions associated with the centrosomal location of BRCA1.
Intracellular localization of BARD1-EGFP and BARD1-EGFP deletion mutants
Mouse BARD1 has three putative NLS sequences located close to or within each functional domain ( Figure 3a ): NLS1 -RKKNSIKMWFSPRSKKV-starting at position 130, NLS2 -PARKRNH-at 408 and NLS3 -RKPK-at 693. When applying Reinhardt's method (http://psort.nibb.ac.jp/) for the prediction of nuclear localization with a reliability coefficient of 94.1%, the prediction for intracellular localization for mouse BARD1 has a 52.2% score for the nucleus, 30.4% for the mitochondria, 13% for the cytoplasm and a 4.3% for the cytoskeleton. Together the cytosolic fraction values add up to 47.8% implying a possible role for BARD1 within the cytoplasm. Human BARD1 has six putative NLS sequences and a higher prediction score for the nucleus of 82.6%. In order to ascertain BARD1's intracellular localization and to determine which domains of BARD1 or which NLS are necessary for nuclear import, we generated either EGFP-tagged full-length mouse BARD1 or deletion mutants (Figure 3a) . Constitutive expression of EGFP-BARD1 fusion proteins was obtained under the transcriptional control of the CMV promoter. To determine the localization of BARD1-EGFP or deletion mutants, we transfected the BARD1-EGFP plasmids in various cell lines and monitored their localization by fluorescent microscopy at different time points (12-30 h) after transfection. The intracellular distribution of all BARD1-EGFP fusion proteins differed greatly from the nuclear and cytoplasmic localization of EGFP alone ( Figure 3b ). The analysis of a number of 8-12 microscopic fields from at least three independent transfection experiments at 24 h after transfection (Figure 3c ), showed that full-length BARD1-EGFP locates to the nucleus more frequently (76%) than to the cytoplasm (24% of the cases). Surprisingly, the D-RING-EGFP and D-HIND-EGFP, which lack the first NLS at position 130, but also lack the BRCA1-interacting RING finger domain, exhibited a most pronounced preference for the nucleus. Interestingly, D-RING-EGFP, which localized exclusively to the nucleus, never aggregates within nuclear dots during the S phase. The RING domain by itself when fused to EGFP localizes evenly to the cytoplasm and nucleus, as did ANK-EGFP (Figure 3b ). Both constructs have only a single NLS. Most interestingly, the C-terminal deletion, D-BRCT-EGFP, localized almost exclusively to the nucleus and formed distinct speckles within the nucleus, as did the full-length BARD1-EGFP. These data indicate that the nuclear localization of BARD1 is independent of BRCA1, since the BARD1 deletion constructs lacking the RING finger have even increased nuclear localization. However, the aggregation within nuclear dots might depend on BRCA1, since neither D-RING-EGFP nor D-HIND-EGFP, or ANK-EGFP concentrate on nuclear dots. The N-terminal region containing the BRCA1 interaction domain might be required but not sufficient for BARD1 localization to nuclear dots.
Mapping of apoptotic function of BARD1
While the function of the conserved RING finger domain is well described, less contributions have been made to elucidate the functional significance of the ankyrin repeats, the BRCT domains, or the intervening sequences. To determine the proapoptotic region of BARD1 and to investigate whether any of the conserved sequence motifs was involved, we analysed the induction of apoptosis by BARD1 deletion mutants missing either RING finger, ankyrin, or BRCT domain (Figure 4 ). Maximal induction of apoptosis, as tested by DNA laddering ( Figure 4a ) and TUNEL staining (Figure 4b ), was observed only with the full-length BARD1 construct. Efficient induction of apoptosis was observed with a variety of deletion mutants (Figure 4c ), namely deletion of the BARD1 C-terminal BRCT domains (D-BRCT), of the region comprising the ankyrin repeats (D-ANK), of the N-terminal domain comprising the RING finger (D-RING), or the deletion of N-terminal and the C-terminal regions (ANK2). One mutant was devoid of apoptosis-inducing activity, namely of the construct expressing the BARD1 N-terminus, RING. From these experiments, it can be concluded that the region sufficient for apoptosis induction includes sequences from amino acid 316 through 604 and that a minimal region required for apoptosis induction comprises sequences from amino acid 510 through 604. To demonstrate that apoptosis induction was directly due to the expression of BARD1, we determined the apoptosis inducing capacity of BARD1-EGFP and BARD1 deletion mutants fused to EGFP in transient transfection assays in TAC-2 cells. With comparable transfection efficiencies, the overexpression of the exogenous BARD1-EGFP proteins induces morphologic changes and nuclear fragmentation, which is not observed with cells transfected with control plasmid EGFP only or in nontransfected cells. All constructs comprising the minimal apoptotic region led to apoptosis induction after transient transfection. Staining with DNA dye DAPI demonstrates that apoptotic cells, recognized by their nuclear fragmentation, are clearly correlated with cells expressing EGFP fusion proteins in the case of BARD1-EGFP, D-RING-EGFP, D-BRCT-EGFP, and ANK-EGFP, while expression of EGFP, or RING-EGFP was not correlated with apoptosis ( Figure 5 ). Inspection of random fields showed that at early time points after transfection (24-48 h) the frequency of apoptosis was lower for D-RING-EGFP, D-HIND-EGFP, and D-BRCT-EGFP than for other deletion mutants or for BARD1-EGFP, and at all times insignificantly low for EGFP and RING-EGFP.
Cytoplasmic localization of BARD1 during apoptosis
Since endogenous and exogenous expression of BARD1 is found in both the nucleus and cytoplasm, it was speculated that the apoptotic function of BARD1 was correlated with its cytoplasmic localization as observed for other gene products of the apoptotic pathway (Conus et al., 2000) . When individual cells were monitored after transient transfection with BARD1-EGFP, it was observed that the EGFP-tagged BARD1, or truncated BARD1, D-RING-EGFP, was translocated from the nucleus to the cytoplasm during apoptosis (Figure 6a ). This was specifically pronounced (Thai et al., 1998; Ghimenti et al., 2002) in cells transfected with D-RING-EGFP that after transfection is located exclusively to the nucleus. To demonstrate that exogenous BARD1 D-RING-EGFP and endogenous BARD1 were both translocated from the nucleus to the cytoplasm during apoptosis, immunofluorescence microscopy was performed on cells transfected transiently with D-RING-EGFP. Staining with anti-BARD1 antibodies (PVC) directed against the RING domain (Irminger-Finger et al., 1998) demonstrates that D-RING-EGFP, not recognized by anti-BARD1-PVC, first localized to the nucleus, then at later stages of apoptosis is translocated to the cytoplasm, while endogenous BARD1, detected with anti-BARD1 antibody PVC, is still localized to nuclear dots. At late stages of apoptosis, both exogenous and endogenous BARD1 are found mostly excluded from the nucleus (Figure 6b ). This observation is consistent with the hypothesis that excess of BARD1 over BRCA1 could lead to cytoplasmic localization of BARD1 and initiation of the apoptotic pathway (Irminger-Finger et al., 2001) .
To further address the apoptosis-related translocation of BARD1, its distribution between nucleus and cytoplasm was assayed after treatment with the apoptosis inducing drug doxorubicin, both by immunofluorescence microscopy and Western blotting. MCF7 cells were analysed with or without doxorubicin treatment. In untreated cells, BARD1 protein levels are very low but higher in the nucleus than in the cytoplasm; upon apoptosis, overall BARD1 levels are increased, but the distribution of BARD1 between the nucleus and cytoplasm is inversed (Figure 7a) . Interestingly, BRCA1 remains localized to nuclear dots after doxorubicin treatment, as observed by staining with anti-BRCA1 antibodies (Figure 7a ). To investigate BARD1 translocation after doxorubicin treatment biochemically, protein extracts from cells treated with doxorubicin were prepared and nuclear and cytoplasmic fractions were analysed on Western blots (Figure 7b ). To follow the translocation of BARD1 to the cytoplasm after BARD1-induced apoptosis, we monitored BARD1 expression in cytoplasmic and nuclear fractions at different time points after treatment. Using antibodies against different regions of BARD1, we observed that full-length 97 kDa BARD1 concentrations were increased at early time points after treatment with doxorubicin, and decreased at later time points. Analysis of nuclear and cytoplasmic extracts demonstrates that the concentration of BARD1 in the nucleus is increased during 6 h of doxorubicin treatment and then decreased. In the cytoplasm, however, BARD1 of 97 kDa is slightly increased and a protein of 67 kDa is massively increased after 5 h of treatment. These data could be explained with the following hypothesis: BARD1 levels increase after apoptosis induction, but excess BARD1 translocates to the cytoplasm and is cleaved and gives rise to the stable C-terminal 67 kDa fragment. The appearance of a C-terminal 67 kDa BARD1 cleavage product is consistent with the previous report that a truncated 67 kDa product of BARD1 accumulates during apoptosis due to cleavage by the caspase-dependent kinase calpain (Gautier et al., 2000) .
Apoptotic function of BARD1 regulated through protein stability
It was observed that BARD1-EGFP and EGFP-tagged deletion constructs did not give rise to identical protein expression levels of the fusion products after transfection. To investigate whether the differences observed were due to differences in transcriptional activity, the regulation of translation, or protein stability, we monitored the expression of BARD1-EGFP and of BARD1 deletion mutants on the level of mRNA and protein expression (Figure 8a-c) . RT-PCR was performed using primers directed against EGFP and BARD1 is localized primarily to the nucleus in untreated cells and translocates to the cytoplasm after UV exposure. Note that low levels of BARD1 in untreated cells were visualized by overexposure of the image. UV exposure was as described previously (IrmingerFinger et al., 2001) . BRCA1 staining was performed with anti-BRCA1 antibody 5-MO. (b) Western blot analysis of nuclear versus cytoplasmic extracts in NIH3T3 cells following exposure to doxorubicin in a time-dependent manner shows increased expression of BARD1 during apoptosis and demonstrates the appearance of a different truncated form of BARD1 found in the cytoplasm. Antibodies used were C-20 (Santa Cruz) recognizing a C-term epitope (** represents the 97 kDa isoform and * the 67 kDa.)
Nuclear-cytoplasmic translocation of BARD1 CE Jefford et al against BARD1. The mRNA expression levels of fulllength BARD1-EGFP and of the diverse BARD1-EGFP deletion mutants were compared by using primers either covering different regions of the mouse BARD1 coding sequence or directed against the GFP portion of the fusion proteins. The mRNA levels were similar in all observed cases (Figure 8a ), indicating that mRNA expression levels were directly correlated to the concentration of plasmid DNA transfected.
To test protein translation potential of the various constructs, in vitro transcription/translation was performed to monitor protein stability in vitro. Full-length BARD1 and deletion mutants were transcribed and translated into protein with similar efficiency, although slightly elevated levels of protein were obtained with the D-RING construct (Figure 8b) . However, protein expression levels after transfection of EGFP-tagged constructs appeared to vary. Western blots were probed with antibodies against GFP in cell extract collected 24 h after transfection. Probing of protein extracts after transfection of the various BARD1 expression constructs exhibited significant differences in expression levels. Highest expression was observed for D-RING-EGFP, less for D-HIND-EGFP and ANK-EGFP, very little for full-length BARD1-EGFP, which was compensated by increasing the protein concentration for BARD1-EGFP loaded on the gel (Figure 8c ). Repeatedly, a C-terminal cleavage product could be detected more readily with anti-GFP antibodies than full-length BARD1-EGFP, suggesting that BARD1 and BARD1 deletion mutants that comprise the N-terminal region of BARD1 are prone for degradation.
Discussion
Nuclear-cytoplasmic distribution of BARD1
The general idea that BARD1 is a nuclear protein is based exclusively on in vitro studies. We have investigated the localization of BARD1 in tissues. In particular, we were interested to determine the intracellular localization of BARD1 in tissues where apoptosis occurs, either physiologically or induced. Our results demonstrate that BARD1 is localized to both the nucleus and the cytoplasm in vivo. We further explored the localization of BARD1 in a variety of cell lines in vitro. Both immunofluorescence and electromicroscopy revealed that endogenous BARD1 resides in the nucleus and the cytoplasm. Using EGFP-tagged BARD1 and BARD1 deletion mutants, we confirmed that all BARD1 deletion proteins were translocated to the nucleus, but a variable proportion of the proteins was also detected in the cytoplasm. These data contrast with previous reports showing that BARD1 is localized exclusively to the nucleus colocalizing with BRCA1 in discreet dots during the S phase (Scully et al., 1997a) . It is possible that in human cells with human BARD1, which has six NLS, the propensity of nuclear localization is higher than that for mouse BARD1, which has only three putative NLS. All BARD1-EGFP fusion proteins, described here, are translocated to the nucleus, indicating that a single NLS sequence is sufficient for the correct addressing of BARD1 to the nucleus. The differential intracellular localization of the EGFPtagged constructs may be correlated with the number of NLS present within each specific construct. Interestingly, the BARD1-RING finger motif is not required for nuclear localization, and nuclear localization of BARD1 is therefore independent of BRCA1. In fact, it has been shown that on the contrary BRCA1 requires BARD1 for entering and remaining in the nucleus, and this is dependent on the BRCA1-RING domain (Fabbro et al., 2002) . Furthermore, we demonstrate that the BRCTdeletion mutant of BARD1 localizes to specific nuclear dots, as does full-length BARD1, but not the RING domain by itself, suggesting that RING is not sufficient for localization of BARD1 in nuclear dots. An alternative localization of BARD1 occurs during apoptosis. BARD1 and a truncated form of BARD1, p67 BARD1, appears in the cytoplasm during apoptosis. This isoform of BARD1 represents the C-terminal portion of the protein, recognized by antibodies directed against 50 C-terminal amino acids. A 67 kDa C-terminal truncated form of BARD1 was reported previously to be generated during apoptosis in various cell lines through cleavage by the caspase-dependent protease calpain (Gautier et al., 2000) . The p67 protein observed in the cytoplasmic fraction is consistent with the accumulation of the p67 BARD1 cleavage product in apoptotic tumor cells (Gautier et al., 2000) .
Apoptosis is triggered by overexpression of a minimal required region of BARD1
Overexpression of all forms of BARD1-EGFP and deletion mutants, with the exception of the RING-EGFP construct, induced apoptosis, based on TUNEL and DNA fragmentation assays, and visualized by the condensed and fragmented nuclear morphology as compared to the EGFP control. Furthermore, using deletion mutants of BARD1, a minimal region required for triggering apoptosis could be determined. As observed with the overexpression of full-length BARD1, cells transfected with BARD1-EGFP, or BARD1-deletion mutants cannot be cultured over time due to the apoptotic effect of the fusion proteins. The minimal region required for the apoptotic function comprises the sequence between the end of the ankyrin repeats and the beginning of the BRCT domain. Interestingly, this region harbors two point mutations (C557S and Q564H) associated with tumors of the breast, ovary, and uterus (Thai et al., 1998; Ghimenti et al., 2002) . In line with these findings, we have previously reported that the mutant Q564H when used in transient transfections is less efficient in apoptosis induction than full-length BARD1 (Irminger-Finger et al., 2001) . Taken together, these data suggest that the primary tumor suppressor function of BARD1 is linked to its BRCA1-independent function in inducing apoptosis.
Protein stability is increased in the absence of the RING domain
When expression of BARD1-EGFP or the tagged fusion proteins was monitored on Western blots, the protein levels varied according to the specific plasmid construct and despite identical transfection conditions and identical plasmid DNA concentrations used. Interestingly, BARD1-EGFP, RING-EGFP and D-BRCT-EGFP constructs showed increased susceptibility for degradation. However, BARD1 protein stability appears to be increased in the absence of the RING domain. Consistent with this observation, all BARD1-EGFP deletion-mutants that bear the RING finger domain have lower expression levels than the mutants lacking the RING domain. One possible explanation for the degradation of these fusion proteins is the reported ubiquitylation activity of the RING domain (Chen et al., 2002) . Possibly, the BARD1-RING domain is a target for protein degradation by the ubiquitin pathway, as speculated for BRCA1 , and BARD1-BRCA1 may target excess BARD1 for degradation, but BARD1-BRCA1 dimer formation protects from degradation. Furthermore, it was also hypothesized that ubiquitylation could act as nuclear export signal, as it is the case for p53 (Gu et al., 2001; Lohrum et al., 2001) , and that BARD1 influences the nuclear export of BRCA1, which is controlled by ubiquitylation . The observation of BARD1 translocation to the cytoplasm, together with its described degradation, suggests that BARD1 translocation could be based on the ubiquitylation, specifically since BARD1 does not have an NES on its own.
The model derived from these observations
It was suggested that the BRCA1/BARD1/Polymerase II holoenzyme complex is the sensor for doublestranded DNA breaks while arresting the cell in S phase for repair mechanisms to occur (Parvin, 2001) . According to our model (Figure 9 ), BARD1 may be the key molecule that could trigger the cell-cycle block as a BARD1-BRCA1 complex and apoptosis through an increase of BARD1. Initiation of apoptosis is accompanied by BARD1 cleavage and accumulation of a stable C-terminal cleavage product, which might represent an irreversible decision for apoptosis. BRCA1 may recruit BARD1 to activate ubiquitylation of the Polymerase II holoenzyme, and provoking its degradation through the proteasome pathway. BRCA1 was suggested to be liberated from BARD1 at later stages , although it is not clear what triggers the separation of BARD1 and BRCA1. In case of a high ratio of BARD1/BRCA1, the excess Figure 9 Model of BARD1 cytoplasmic translocation. BARD1 enables BRCA1 to be transported to the nucleus. Excess BARD1 is translocating to the cytoplasm more readily. However, full-length BARD1 might be exported and degraded. BARD1 degradation depends on the presence of the RING structure. A C-terminal fragment, p67 BARD1, presumably due to proteolytic cleavage, is stable and found in the cytoplasm. p67 BARD1 is no binding partner for BRCA1 but has apoptotic activity BARD1 is found in the cytoplasm and might be degraded, but the cleavage mechanism that eliminates the N-terminal sequences including the RING domain produces a stable C-terminal portion of BARD1. This p67 cleavage product of BARD1 is mimicked by the deletion mutant D-RING. Since D-RING retains apoptotic activity, it is likely that the cleaved form of BARD1 has an apoptotic function. Most importantly, both the BARD1 cleavage product p67 and D-RING are devoid of the RING finger and seem more resistant against degradation. Therefore the cleavage of BARD1 during apoptosis could provide a positive regulatory feedback loop upon apoptosis induction.
In conclusion, BARD1 has at least five different functions in binding to BRCA1, all of which are disrupted by mutations that effect the interaction of BRCA1with BARD1: (1) tumor suppression and genetic instability (Wu et al., 1996; Ruffner et al., 2001) , (2) colocalization in nuclear dots upon genotoxic stress (Scully et al., 1997a, b) , (3) nuclear translocation of BRCA1 (Fabbro et al., 2002) , (4) ubiquitin ligase activity of the BARD1/BRCA1 heterodimer (Hashizume et al., 2001; Chen et al., 2002) , (5) recruiting of Polymerase II holoenzyme (Chiba and Parvin, 2002) . The localization of BARD1 in nuclear dots requires RING domain, but also the additional domains that might promote binding of other proteins than BRCA1, since the BARD1-RING domain by itself does not localize to nuclear dots. It could be concluded, that fulllength BARD1 might be required for BRCA1-dependent functions associated with nuclear localization, but a C-terminal portion of BARD1 is sufficient for apoptotic activity, associated with cytoplasmic localization (Figure 9 ).
Materials and methods
Cell cultures
TAC-2 cells is a clonal subpopulation derived from the NMuMG normal murine mammary gland epithelial cell line (CRL 1636; American Type Culture Collection, Rockville, MD, USA). They were cultured in collagen-coated tissue culture dishes in high-glucose DMEM supplemented with 10% fetal calf serum (FCS), penicillin (110 mg/ml) and streptomycin (110 mg/ml). The Human Embryonic Kidney HEK 293T cell line, as well as HeLa cell lines, were obtained from the American Tissue Type Culture Collection. NIH-3T3 and MCF-7 cell lines were purchased from the NIH (Bethesda, MD, USA). All cell lines were cultured in 10 cm plastic tissue culture dishes (NUNC, Roskilde, Denmark) and incubated at 371C in humidified air containing 5% CO 2 . Adherent subcultures were detached from culture dishes using a solution of Trypsin/EDTA in HBSS without Ca 2 þ or Mg 2 þ . Subconfluent cell cultures were passaged regularly at 1 : 10 dilution twice a week. All cell culture media, solutions, buffers and antibiotics were purchased from GIBCO (Invitrogen AG, Basel, Switzerland).
Plasmid constructions
Two sets of deletion mutants were generated with and without the EGFP fusion tag. The full-length mouse cBARD1 (Irminger-Finger et al., 1998) was used to generate the following constructs in pcDNA3 behind a CMV promoter: (1) full-length BARD1 (aa 1-765); (2) DRING (aa 137-765) using the EcoRI(396) restriction site; (3) DBRCT (aa 1-604) ScaI(1812); (4) DANK (aa 1-316/510-765) Stu/Hpa; (5)ANK2 (aa 316-604) StuI/ScaI; (6) RING (aa 1-266) EcoRI. The plasmid pEGFP-N1 (Enhanced Green Fluorescent Protein) was purchased from Clontech and was used to generate either the full-length BARD1-EGFP or BARD1 deletion bearing mutants fused in frame with the EGFP tag. The following inserts were ligated in frame with the EGFP: (1); (2); (3); (6) and (7) DHIND (aa 394-765); (8) ANK (aa 316-604).
Transfection and whole-cell extract preparation Cells were seeded in 10 cm Petri dishes and transfected with 2 mg of DNA using the Effectene reagents by Qiagen. Cells were harvested at 18, 24 and 48 h post-transfection. They were centrifuged and washed once in PBS, resuspended in 0.3 ml of ice-cold radio immunoprecipitation assay (RIPA) buffer (150 mM NaCl, 1% Nonidet P-40, 0.5% NaDOC, 0.1% SDS, 50 mM Tris, pH 8.0, 2 mM EDTA, pH 8.0) and supplemented with protease inhibitors (1 mM PMSF, 3 mg/ml aprotinin, 10 mg/ml leupeptin)). Cells were incubated on ice for 30 min. The extracts were centrifuged at 13 000 g in a microcentrifuge for 15 min at 41C in order to remove cell debris and clear the cell lysate.
Nuclear and cytoplasmic fractions
For separation of cytosolic fraction, cells were incubated in Lysis Buffer (Triton X-100 (1%), HEPES pH 7.6. (50 mM), NaCl (150 mM), NaF (100 mM), Na-pyrophosphate (50 mM), EDTA (4 mM), Na 3 VO 4 (10 mM)) supplemented with protease inhibitors (as above) and rotated at 41C for 30 min. Supernatant was separated from nuclear fractions by centrifugation at 13 000 r.p.m. for 15 min. The pellet was washed in the Wash Buffer (Lysis Buffer þ 25% glycerol) and centrifuged once more as above. The supernatant wash was added to cytosolic fraction. Nuclear fraction was lysed in the nuclear lysis buffer (NLB) (Wash Buffer with 330 mM NaCl), sonicated, incubated on ice for 30 min and centrifuged as above to separate cell debris from nuclear fraction.
Western blots
In vitro transcription/translation products were obtained using a kit from Promega. Equal concentrations of all in vitro transcription/translation, whole-cell extracts as well as cytosolic and nuclear fractions per gel were loaded onto SDS-PAA gels according to Laemmli's protocol and were transferred to polyvinylidene fluoride (PVDF) membranes. All primary antibodies were incubated at room temparature (RT) at indicated dilutions for 1 h in TBS/5% nonfat dry milk and washed five times 3 min in TBS/0.1% Tween 20. Secondary HRP-conjugated antibodies were incubated at a 1 : 2000 dilution (Santa Cruz) at RT for 1 h, and bands were revealed using the Enhanced Chemiluminescence (ECL) system by Boehringer.
Antibodies
The anti-BARD1 (N-19, C-20, H-300), and anti-p53 (FL-393) antibodies were purchased from Santa Cruz. Anti-BRCA1 (5-MO) was a generous gift from Dr A Vincent and G Lenoir. Anti-GFP (TP-401) was purchased from Chemokine (Torrey Pines Biolabs, Houston, TX, USA)). PVC is a previously described anti-BARD1 antibody (Irminger-Finger et al., 1998).
Secondary conjugated antibodies to horseradish peroxidase (HRP) were purchased from Santa Cruz and were compatible with Cruz Molecular Weight Markers (Santa Cruz, CA, USA).
Assessment of apoptosis
Cells were harvested 48 h post transfection. Trypsinized cells were centrifuged and washed once with PBS prior assay. Quantification of apoptosis was measured by performing TUNEL assay, using the APO-DIRECT kit (Pharmingen). At least 10 000 events were measured on a flow cytometer from DAKO corporation and analysed using the software package FlowMax from PARTEC. Assessment of DNA fragmentation was performed with Suicide-Track DNA isolation kit (Oncogene) and DNA ladders were stained with ethidium bromide on 1% agarose gels.
Fluorescence microscopy
Cells were seeded on glass coverslips in 6-well culture dishes or plated on an 8-well coverslide and transfected or not with the aforementioned plasmids. Cells were washed in HBSS, and either fixed 2% paraformaldehyde (PFA) in Hank's balanced salt solution (HBSS) 15 min at RT or in methanol for 6 min at À201C and rinsed in acetone for 30 s. Coverslides were mounted and observed under a Nikon epi-fluorescence microscope and images captured with a 3.3 mega-pixel CCD camera and processed with MetaMorph software (Visitron).
Tissue preparation for immunohistochemistry
Two adult male mice Balb/c were used in this part of the study. This study was conducted according to the rules written by the Swiss veterinary office (Bern). The animals were killed by cervical dislocation. After the animals were killed, the thoracic aorta was cannulated and the vasculature flushed with sodium chloride solution (0.9 g/l). The fixation was performed by perfusion with 2% glutaraldehyde and 2% paraformaldehyde in 0.05 M phosphate buffer, pH 7.4.
Immunohistochemistry
The immersion-fixed mouse brain and spleen were embedded in paraffin. Consecutive orthogonal 5 mm sections were mounted on polylysine-coated slides. Sections were counterstained with hematoxylin/eosin (HM). The first section of each set of sections was stained HM and used to determine tubule stages. The remaining sections were further processed for immunocytochemical staining. The endogenous peroxidase was quenched by 15-min incubation in 2% hydrogen peroxide in PBS. Unmasking of the epitopes was carried out by boiling the deparaffinized rehydrated sections for 10 min (two times, 5 min each) in 10 mM citrate buffer, pH 6.0, using a microwave oven at 5000 W power output. Primary antibodies were used in a 1 : 50 dilution.
Immunogold labeling and silver enhancement for EM Cells were fixed with 3% freshly depolymerized paraformaldehyde and 0.15%. glutaraldehyde in 0.1 M phosphate buffer (PB) pH 7.2 for 1 h at room temperature. They were then permeabilized with PB containing 0.1% Triton X-100. The immunostaining was then performed using ultrasmall gold conjugates and R-Gent SE-EM silver enhancement reagent using the Aurion Kit (Biovalley, Marne-la-Valle´e, France) as indicated by the manufacturer. Primary antibody used was C-20 diluted at 1/100. After immunostaining, the cells were postfixed for 1 h at 41C with osmium tetraoxide buffered at pH 7.2 with symmetric collidin. After two washes in the same buffer, the preparations were dehydrated through a series of graded ethanol and propylene oxide, and the pellets embedded in Epon 812 medium. Ordinary thin sections were then cut with a Reichert ultramicrotome, stained with uranyl acetate and lead citrate, or left unstained. All sections were then examined and photographed under a JEM electron microscope.
Note added in proof
Coincidentally, our results are corroborated by similar findings (Rodriguez et al., 2003) published recently in this journal as our article was undergoing final revision.
